Franklin Biotechnology Discovery Fund

Portfolio Statistics

Assets

Total Fund AssetsAs of 04/30/2021 (updated monthly) $1,449.3 (M)
Net Assets - Class C As of 03/31/2021 (updated monthly) $65.7 (M)
P/E Ratio (12-mo Forward)As of 03/31/2021 (updated monthly) 13.39
P/B RatioAs of 03/31/2021 (updated monthly) 5.13

Positions As of 04/30/2021

Portfolio Details

Asset AllocationAs of 04/30/2021

[name] [value]
Equity 96.21%
Cash & Cash Equivalents 3.79%

Geographic BreakdownAs of 04/30/2021

[name] [value]
United States 89.68%
Cash & Cash Equivalents 3.79%
Denmark 2.23%
Canada 1.86%
Switzerland 1.18%
Netherlands 1.12%
United Kingdom 0.14%

sector breakdownAs of 03/31/2021

[name] [value]
Biotechnology 76.87%
Pharmaceuticals 14.81%
Life Sciences Tools & Services 4.00%
Cash & Cash Equivalents 2.25%
Diversified Capital Markets 1.59%
Other Diversified Financial Services 0.35%
Health Care Facilities 0.14%

TOP TEN HOLDINGSAs of 04/30/2021

40.38%
Other
0% 100%
[holdings-table-heading]
GILEAD SCIENCES INC 6.08%
AMGEN INC 5.27%
REGENERON PHARMACEUTICALS INC 4.59%
VERTEX PHARMACEUTICALS INC 4.23%
ILLUMINA INC 4.09%
NOVAVAX INC 3.95%
HORIZON PHARMA PLC 3.56%
BIOGEN INC 3.13%
IOVANCE BIOTHERAPEUTICS INC 3.03%
MIRATI THERAPEUTICS INC 2.45%